| + |
CSNK2A2 |
phosphorylation
|
MS4A1 |
0.311 |
| Identifier |
Residue |
Sequence |
Organism |
Cell Line |
| SIGNOR-251011 |
Ser231 |
KSNIVLLsAEEKKEQ |
Homo sapiens |
B-lymphocyte |
| pmid |
sentence |
| 7678037 |
These data suggest taht CKII can phosphorylate more than one site on CD20 molecule. | Taken together, this data shown that insulin can increase serine/ threonine phosphorylation and may stimulate CKII activity in B cells. |
|
| Identifier |
Residue |
Sequence |
Organism |
Cell Line |
| SIGNOR-251012 |
Ser289 |
PPQDQESsPIENDSS |
Homo sapiens |
B-lymphocyte |
| pmid |
sentence |
| 7678037 |
These data suggest taht CKII can phosphorylate more than one site on CD20 molecule. | Taken together, this data shown that insulin can increase serine/ threonine phosphorylation and may stimulate CKII activity in B cells. |
|
| Identifier |
Residue |
Sequence |
Organism |
Cell Line |
| SIGNOR-251013 |
Thr250 |
KEEVVGLtETSSQPK |
Homo sapiens |
B-lymphocyte |
| pmid |
sentence |
| 7678037 |
These data suggest taht CKII can phosphorylate more than one site on CD20 molecule. | Taken together, this data shown that insulin can increase serine/ threonine phosphorylation and may stimulate CKII activity in B cells. |
|
| Publications: |
3 |
Organism: |
Homo Sapiens |
| + |
CSNK2A1 |
phosphorylation
|
MS4A1 |
0.311 |
| Identifier |
Residue |
Sequence |
Organism |
Cell Line |
| SIGNOR-250915 |
Ser231 |
KSNIVLLsAEEKKEQ |
Homo sapiens |
|
| pmid |
sentence |
| 7678037 |
These data suggest taht CKII can phosphorylate more than one site on CD20 molecule. | Taken together, this data shown that insulin can increase serine/ threonine phosphorylation and may stimulate CKII activity in B cells. |
|
| Identifier |
Residue |
Sequence |
Organism |
Cell Line |
| SIGNOR-250916 |
Ser289 |
PPQDQESsPIENDSS |
Homo sapiens |
|
| pmid |
sentence |
| 7678037 |
These data suggest taht CKII can phosphorylate more than one site on CD20 molecule. | Taken together, this data shown that insulin can increase erine threonine phosphorylation and may stimulate CKII activity in B cells. |
|
| Identifier |
Residue |
Sequence |
Organism |
Cell Line |
| SIGNOR-250917 |
Thr250 |
KEEVVGLtETSSQPK |
Homo sapiens |
B-lymphocyte |
| pmid |
sentence |
| 7678037 |
These data suggest taht CKII can phosphorylate more than one site on CD20 molecule. | Taken together, this data shown that insulin can increase erine threonine phosphorylation and may stimulate CKII activity in B cells. |
|
| Publications: |
3 |
Organism: |
Homo Sapiens |
| + |
obinutuzumab | down-regulates activity 
binding
|
MS4A1 |
0.4 |
| Identifier |
Residue |
Sequence |
Organism |
Cell Line |
| SIGNOR-259896 |
|
|
Homo sapiens |
Chronic Lymphocytic Leukemia Cell, Follicular Lymphoma Cell |
| pmid |
sentence |
| 28584136 |
Obinutuzumab (OBZ) is a recombinant type II anti-CD20 and immunoglobulin G1 Fc-optimized monoclonal antibody (mAb), recently approved in chronic lymphocytic leukemia (CLL; B-cell CLL) and follicular lymphoma (FL). |
|
| Publications: |
1 |
Organism: |
Homo Sapiens |
| + |
ofatumumab | down-regulates activity
binding
|
MS4A1 |
0.4 |
| Identifier |
Residue |
Sequence |
Organism |
Cell Line |
| SIGNOR-259897 |
|
|
Homo sapiens |
Chronic Lymphocytic Leukemia Cell |
| pmid |
sentence |
| 28580841 |
Ofatumumab is a human IgG1κ monoclonal antibody that binds to a membrane-proximal epitope of CD20 molecule expressed on the surface of B lymphocytes. Ofatumumab, the second-generation anti-CD20 antibody, induces cell lysis through complement-dependent cytotoxicity (CDC) and antibody-dependent cellular cytotoxicity. Ofatumumab is approved as monotherapy and in combination with chlorambucil for the treatment of fludarabine- and alemtuzumab-refractory CLL patients and previously untreated CLL patients, respectively. |
|
| Publications: |
1 |
Organism: |
Homo Sapiens |
| + |
rituximab | down-regulates activity
binding
|
MS4A1 |
0.4 |
| Identifier |
Residue |
Sequence |
Organism |
Cell Line |
| SIGNOR-259902 |
|
|
Homo sapiens |
|
| pmid |
sentence |
| 20350663 |
Rituximab is a class I chimeric anti-CD20 antibody that has shown efficacy in chronic lymphocytic leukemia (CLL), both as a single agent and in combination with traditional chemotherapies. |
|
| Publications: |
1 |
Organism: |
Homo Sapiens |
| + |
ibritumomab tiuxetan | down-regulates activity
binding
|
MS4A1 |
0.4 |
| Identifier |
Residue |
Sequence |
Organism |
Cell Line |
| SIGNOR-259893 |
|
|
Homo sapiens |
|
| pmid |
sentence |
| 27497027 |
Zevalin® (ibritumomab tiuxetan) is a radioactive drug product, which is the combination of a β-emitting isotope, 90Y, linked to the anti-CD20 monoclonal antibody (mAb), rituximab. It has demonstrated therapeutic efficacy with durable responses and allows delivery of ionizing radiation directly to the tumor site, while minimizing toxicity to normal tissue. Ibritumomab tiuxetan is indicated for treatment of patients with relapsed or refractory low-grade, follicular NHL |
|
| Publications: |
1 |
Organism: |
Homo Sapiens |
| + |
tositumomab and iodine i 131 tositumomab | down-regulates activity
binding
|
MS4A1 |
0.4 |
| Identifier |
Residue |
Sequence |
Organism |
Cell Line |
| SIGNOR-259903 |
|
|
Homo sapiens |
|
| pmid |
sentence |
| 14748653 |
Tositumomab is an immunoglobulin G murine monoclonal antibody that binds to the CD20 antigen on the surface of normal and malignant human B-cells. Tositumomab is linked covalently with iodine-131 to produce the radioimmunoconjugate iodine-131 tositumomab (Bexxar). The iodine-131 tositumomab regimen was approved by the US Food and Drug Administration in June 2003 for the treatment of patients with CD20-positive, follicular non-Hodgkin's lymphoma, both with and without transformation, whose disease is refractory to rituximab (Rituxan) and has relapsed following chemotherapy. |
|
| Publications: |
1 |
Organism: |
Homo Sapiens |
3.0
MS4A1
- 
- 